Shots:
- For smaller volume agreements, the company has priced its COVID-19 vaccine ranging from $32-$37/ dose, higher than the price of Pfizer’s vaccine candidate
- The company is in talks with several countries for supply agreements of its vaccine, adding that it had already received about $400M for supply. The P-III study of mRNA-1273 is being conducted in collaboration with NIH and BARDA with an anticipated completion of enrollment in Sept’2020
- Moderna has received $1B from the US government under a plan to ramp up vaccine development. The company’s vaccine candidate is one of the few that have already advanced to the final stage of testing
Click here to read full press release/ article | Ref: Reuters | Image: PharmaShots
